| 摘要 |
Formulation comprises a particulate medicament (I) e.g. salmeterol, salbutamol, fluticasone propionate, becolomethasone dipropionate and a fluorocarbon or hydrogen-contg chlorofluorocarbon propellant. Also claimed are the prepn of the surface-modified medicament and a canister for delivering metered doses of the aerosol formulation. Pref., (I) is salmeterol xinafoate (Ia); salbutamol sulphate; fluticascone propionate; beclomethasone dipropionate; or a combination of salmeterol xinafoate and fluticasone propionate; or salbutamol and beclomethasone dipropionate. The propellant is pref. 1,1,1,2-tetrafluoroethane (II). (I) is present in an amt. of 0.005-10% wt. based on the total wt. of the formulation e.g. a salbutamol salt and 1,1,1,2-tetrafluoroethane in a ratio of 0.05:18 by wt. Surface-modified (I) are prepd. by admixture of particulate (I) with a non-polar, non-solvent liq. followed by removal of the lid. |
